Management noted that while U.S. treatment volumes remained flat due to elevated mortality and missed treatments, they maintain a long-term target of 2% plus growth as mortality patterns normalize.The company is pivoting from a turnaround phase to the 'FME Reignite' strategy, focusing on high-volume hemodiafiltration (HDF) to drive long-term mortality reduction and operational efficiency.Care Enablement faced significant headwinds in China due to volume-based procurement and regulatory policy changes that d ...